0000000000223679

AUTHOR

Maria Caterina Putti

showing 4 related works from this author

Recombinant erythropoietin vs. blood transfusion care in infants with hereditary spherocytosis: a retrospective cohort study of A.I.E.O.P. patients (…

2017

MalePediatricsmedicine.medical_specialtyBlood transfusionReticulocytesAnemiamedicine.medical_treatmentSpherocytosisSpherocytosisMEDLINEErythrocyte Count; Erythropoietin; Female; Follow-Up Studies; Hemoglobins; Humans; Infant; Infant Newborn; Italy; Male; Recombinant Proteins; Reticulocytes; Retrospective Studies; Spherocytosis Hereditary; Blood Transfusion; HematologyHereditary spherocytosis03 medical and health sciencesHemoglobins0302 clinical medicinemedicineHumansBlood TransfusionRecombinant erythropoietinErythropoietinErythrocyte Count; Erythropoietin; Female; Follow-Up Studies; Hemoglobins; Humans; Infant; Infant Newborn; Italy; Male; Recombinant Proteins; Reticulocytes; Retrospective Studies; Spherocytosis Hereditary; Blood TransfusionRetrospective Studiesbusiness.industryInfantRetrospective cohort studyHematologymedicine.diseaseNewbornRecombinant ProteinsSurgeryHereditaryItalyErythropoietin030220 oncology & carcinogenesisErythrocyte Count030211 gastroenterology & hepatologyFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine ther…

2013

Background: Due to the limited data available in literature, the aim of this multi-centre study was to prospectively compare in thalassemia major (TM) patients the efficacy of combined deferiprone (DFP) and deferoxamine (DFO) regimen versus either DFP and DFO in monotherapy by cardiovascular magnetic resonance (CMR) over a follow up of 18 months. Methods: Among the first 1135 TM patients in the MIOT (Myocardial Iron Overload in Thalassemia) network, we evaluated those who had received either combined regimen (DFO + DFP, N=51) or DFP (N=39) and DFO (N=74) monotherapies between the two CMR scans. Iron overload was measured by T2* multiecho technique. Biventricular function parameters were qua…

MaleLiver Iron ConcentrationTime FactorsThalassemiaVentricular Function Leftchemistry.chemical_compoundMedicineDeferiproneProspective StudiesMedicine(all)Ejection fractionRadiological and Ultrasound TechnologyBeta thalassemiaDeferoxamineTreatment OutcomeItalyLiverCardiologyThalassemiaDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineDeferiproneCardiomyopathiesmedicine.drugAdultmedicine.medical_specialtyCombination therapyPyridonesChelation therapyMagnetic Resonance Imaging CineDeferoxamineIron Chelating AgentsYoung AdultPredictive Value of TestsInternal medicineHumansRadiology Nuclear Medicine and imagingChelation therapyAnalysis of VarianceChi-Square Distributionbusiness.industryResearchMyocardiumbeta-ThalassemiaStroke Volumemedicine.diseaseSurgerychemistryVentricular Function RightCardiovascular magnetic resonancebusinessJournal of Cardiovascular Magnetic Resonance
researchProduct

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative…

2010

Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare the effectiveness of deferasirox, deferiprone and desferrioxamine on myocardial and liver iron concentrations and bi-ventricular function in thalassemia major patients by means of quantitative magnetic resonance imaging. Design and Methods From the first 550 thalassemia subjects enrolled in the Myocardial Iron Overload in Thalassemia network, we retrospectively selected thalasse…

medicine.medical_specialtyLiver Iron ConcentrationthalassemiaThalassemiairon chelation therapycardiac magnetic resonance imagingGastroenterologythalassemia; iron chelation therapy; cardiac magnetic resonance imagingNOchemistry.chemical_compoundCardiac magnetic resonance imagingInternal medicinemedicinemedicine.diagnostic_testbusiness.industryDeferasiroxBeta thalassemiaMagnetic resonance imagingHematologymedicine.diseaseSurgeryDeferoxaminechemistrybusinessDeferipronemedicine.drug
researchProduct

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

2014

The outcome of high-risk (HR) Acute Lymphoblastic Leukemia (ALL) patients enrolled in AIEOP-BFM ALL 2000 study (NCT00613457) in Italy is described. Overall, 1999 Philadelphia negative ALL patients entered the study. HR criteria were: minimal residual disease (MRD) levels ≥10-3 at day 78 (HR-MRD), no complete remission (no-CR) at day 33, t(4;11) translocation, Prednisone Poor Response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, maintenance. 312 HR patients (15.6% of the total) had 5-year event-free survival (EFS) and overall survival (OS) of 58.9%(SE 2.8) and 68.9%(2.6). In hierarchical ord…

Malemedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentImmunologyChromosomal translocationhigh riskacute lymphoblastic leukemiaHematopoietic stem cell transplantationBiochemistryGastroenterologyAdolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Remission Induction; Treatment Outcome; Hematology; Biochemistry; Cell Biology; ImmunologyPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy Protocolshigh risk; acute lymphoblastic leukemiaHumansMedicineNeoplasmPreschoolChildChemotherapyAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInfantCell BiologyHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyMinimal residual diseaseSurgeryClinical trialRadiation therapyTreatment OutcomeN/ASettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAResidualChild PreschoolNeoplasmFemalebusinessHumanmedicine.drugBlood
researchProduct